MGRXHealthcare · Health Information Services

MGRX Stock Forecast: Mangoceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026

$0.54

−3.77% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 1 Aug 2026 — in the lower half.

Market cap

$9.6M

Ticker Nerd rank

25 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−1.3%

+14.0%

YTD

−27.6%

−68.7%

From 52W high

−80.4%

From 52W low

+230.9%

$0.16

$2.74

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

MGRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mangoceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Size

Volatility

Momentum

Growth

Revisions

Quality

Value

Issuance

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Mangoceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

MGRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

MGRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Mangoceuticals, Inc. (MGRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.3×
Price / sales: 23.1×
Price / book: 0.7×
EV / EBITDA: −0.6×

Growth & margins

Revenue growth (YoY): −37.9%
Earnings growth (YoY): −37.9%
Gross margin: 42.7%
Operating margin: −4588.4%
Net margin: 54.9%

Returns & dividend

Return on equity: −113.9%
Return on assets: −60.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MGRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services

Company	Market cap	TKN rank
MGRXMangoceuticals, Inc.	$9.6M	25
BFRGBullFrog AI Holdings, Inc.	$10.2M	29
ACONAclarion, Inc.	$5.5M	23
VSEEVSee Health, Inc.	$4.4M	31
BEATHeartBeam, Inc.	$26.8M	37
ONMDOneMedNet Corp.	$39.5M	27
MNDRMobile-health Network Solutions	$2.2M	14

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGRX appears on the weeks it earns a place.

News

Latest MGRX news & analysis

Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

Newsfile Corp · 30 July 2026positive

Nuclea Energy Inc., an advanced nuclear technology company, has entered into a definitive business combination agreement with Mangoceuticals, Inc. (NASDAQ: MGRX), providing Nuclea a path to a Nasdaq public listing to advance its Morpheus microreactor.

Why it matters — The business combination would transition MGRX from its current business into a publicly traded advanced nuclear technology company, potentially transforming the company's entire strategic direction.

Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

GlobeNewsWire · 30 July 2026positive

Mangoceuticals, Inc. (MGRX) announced it has entered into a definitive business combination agreement with Nuclea Energy Inc., an advanced nuclear technology company developing the lead-cooled Morpheus microreactor.

Why it matters — This agreement signals Mangoceuticals' pivot into the nuclear energy sector, which could significantly change the company's business focus and market positioning as it brings Nuclea's microreactor technology to public markets amid rising power demand from AI and data centers.

FAQ

Frequently asked questions about MGRX stock

How does Ticker Nerd's model rank MGRX?

As at 1 Aug 2026, Mangoceuticals, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

What is the MGRX stock forecast for 2030?

No analyst covering Mangoceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGRX are extrapolating price history, which says nothing about the business.

How has MGRX stock performed over the past year?

Mangoceuticals, Inc. returned -68.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mangoceuticals, Inc. do?

Mangaceuticals Inc. operates as a biotechnology company specializing in the development of plant-based pharmaceuticals.

What is the latest news on MGRX?

The most recent item we track (Newsfile Corp, 30 July 2026): "Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor". Nuclea Energy Inc., an advanced nuclear technology company, has entered into a definitive business combination agreement with Mangoceuticals, Inc. (NASDAQ: MGRX), providing Nuclea a path to a Nasdaq public listing to advance its Morpheus microreactor.

Company

About Mangoceuticals, Inc.

Mangaceuticals Inc. operates as a biotechnology company specializing in the development of plant-based pharmaceuticals. Its primary function is to harness the medicinal properties of exotic fruits and plants, particularly those with potential health benefits, to create pharmaceutical and nutraceutical products. Mangaceuticals Inc. focuses on research and innovation, employing cutting-edge biotechnological techniques to explore the therapeutic potential of natural compounds. The company's offerings have implications across multiple sectors, notably healthcare, wellness, and pharmaceuticals, as it seeks to provide natural alternatives to conventional medicines. The market significance of Mangaceuticals Inc. lies in its commitment to sustainability and the growing consumer demand for natural and holistic healthcare solutions. By integrating the principles of biotechnology and phytotherapy, the company positions itself at the forefront of a niche market segment that values environmental responsibility and health-conscious products. Mangaceuticals Inc. continues to expand its research and development capabilities, aiming to contribute to the evolving landscape of plant-based medicine and meet the needs of a health-aware global population.

CEO Mr. Jacob D. Cohen · 3 employees · United States · https://www.mangoceuticals.com